Latest News
Avalo Therapeutics, Inc.
- This Avalo Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
- Avalo Therapeutics downgraded to Neutral at Guggenheim after AbbVie data
- Guggenheim downgrades Avalo Therapeutics stock rating on IL-1 data
- Guggenheim Downgrades Avalo Therapeutics to Neutral From Buy
- Avalo Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Alpha male in HS? Abbvie phase III data subdue Avalo shares
- Avalo Therapeutics Down Nearly 40%, On Pace for Largest Percent Decrease Since June 2023 -- Data Talk
- H.C. Wainwright reiterates Avalo Therapeutics stock rating at buy
- Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- Three new hires receive options to buy Avalo shares for $15.47 each
Headlines from the last 30 days, linking to the original publishers. See all market news →